Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard‐dose azacitidine

Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard‐dose azacitidine

Abstract Background Hypomethylating agents, including azacytidine (AZA), are standard therapeutics for patients with high‐risk myelodysplastic syndromes (MDS), a group of myeloid neoplasms. However, treatment schedules are not unified in real‐world practice; in addition to the standard 7‐day (standa...

Full description

Bibliographic Details
Main Authors: Shinichi Ogawa, Tatsuhiro Sakamoto, Ryota Matsuoka, Kantaro Ishitsuka, Yasuko Ogino, Ayano Sootome, Kenichi Makishima, Chikashi Yoshida, Yufu Ito, Seiichi Shimizu, Takuya Suyama, Atsushi Shinagawa, Takayoshi Ito, Naoshi Obara, Manabu Kusakabe, Mamiko Sakata‐Yanagimoto, Yasushi Miyazaki, Yasuhito Nannya, Shigeru Chiba
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Cancer Reports
Subjects:
azacitidine
dose
myelodysplastic syndrome
platelet counts
sex
Online Access:https://doi.org/10.1002/cnr2.1938

Internet

https://doi.org/10.1002/cnr2.1938

Similar Items